MAINZ BIOMED N.V. (MYNZ) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
MYNZ currently has 14.7M outstanding shares. with significant dilution risk as 12.2M authorized shares could dilute existing holders by 83.5%. The company has significantly diluted shareholders by 456.75% over the past 2 years, indicating aggressive capital raising.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| May 18, 2026 |
8-K filing: Quantum Cyber N.V. entered into an Advisory Agreement to issue 5,000,000 shares to an advisor and an Intellectual Property License Agreement with BP United involving a commitment to issue 20,000,000 shares of common stock. |
15M | 12M |
| May 15, 2026 |
10-Q filing | 14.7M shares outstanding |
15M | 12M |
| Mar 31, 2026 |
10-K filing | 12.5M shares outstanding |
13M | 12M |
| Jul 30, 2025 |
F-1 filing: Mainz Biomed N.V. is offering ordinary units, pre-funded units, and ordinary shares underlying warrants and pre-funded warrants pursuant to a registration statement on form F-1 with Maxim Group LLC acting as placement agent. |
2.3M | 12M |
| May 14, 2025 |
F-1 filing: This F-1 filing registers the offering of ordinary units and pre-funded units, each including ordinary shares and warrants, by Mainz Biomed N.V. with Maxim Group LLC acting as the placement agent. |
2.3M | 7.1M |
| Mar 31, 2025 |
20-F filing | 2.3M shares outstanding |
2.3M | 7.1M |
| Apr 09, 2024 |
20-F filing | 21.2M shares outstanding |
21M | 7.1M |
| Apr 07, 2023 |
20-F filing | 14.6M shares outstanding |
15M | 7.1M |
| Dec 30, 2022 |
F-3 filing: The company is filing an F-3 to register ordinary shares, preferred shares, warrants or units up to an aggregate initial offering price of $150,000,000. |
14M | 7.1M |
| May 03, 2022 |
20-F filing | 12.0M shares outstanding |
12M | 0 |